ArticleFrontiers in pharmacology2026
A novel role of the TNF-α/p65/IRF1 axis in aggravating rheumatoid arthritis through the induction of fibroblast-like synoviocytes pyroptosis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by aberrant proliferation and activation of fibroblast-like synoviocytes (FLSs), leading to production of inflammatory mediators. Although interferon regulatory factor 1 (IRF1) is known to participate in immune regulation, its specific role and upstream activation mechanism in RA-FLSs remain elusive. Methods: IRF1 expression was assessed in RA synovial tissues, collagen-induced arthritis (CIA) mouse synovium, and TNF-α-stimulated RA-FLSs. Functional assays evaluated pyroptosis after IRF1 knockdown. Mechanistic investigations included ChIP-seq, Cut-and-Run, and luciferase reporter assays to identify IRF1 target genes and promoter binding. Results: IRF1 was significantly upregulated in RA tissues and TNF-α-treated FLSs. IRF1 suppression attenuated pyroptosis and reduced pyroptosis-associated proteins (CASP1, GSDMD-N, IL-1β, IL-18). TNF-α activated p65, which directly bound to the IRF1 promoter, increasing IRF1 expression. IRF1 directly bound to the CASP1 promoter, enhancing CASP1 expression and pyroptosis. In CIA mice, IRF1 modulation markedly alleviated arthritis symptoms. Conclusion: The TNF-α-p65-IRF1-CASP1 axis drives pyroptosis in RA-FLSs and contributes to RA pathogenesis, identifying IRF1 as a promising therapeutic target value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.